Pfizer executives said people whose COVID-19 symptoms rebound after taking the antiviral Paxlovid should repeat the treatment, though federal guidelines only recommend one five-day treatment course, Bloomberg reported May 3.
Read the full post on Becker's Hospital Review - Healthcare News
